ArticleJTO clinical and research reports2026

Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.

Marina Chiara Garassino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.